- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02292433
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
tiistai 16. helmikuuta 2016 päivittänyt: Pfizer
A Phase 1, Randomized, Double-blind, Placebo-controlled, 3- Period, Crossover Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Two Dose Levels of Pf-04937319 In Japanese Subjects With Type 2 Diabetes Mellitus as Monotherapy
Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
12
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Tokyo
-
Hachioji-shi, Tokyo, Japani, 192-0071
- P-one clinic, Keikokai medical corporation
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
20 vuotta - 64 vuotta (Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- Patients with type 2 diabetes, on diet/exercise therapy only or background therapy with 1 oral anti-diabetic agent (excluding Actos)
Exclusion Criteria:
- Patients with cardiovascular event
- Patients with diabetic complications
- Female subjects who are pregnant or planning to become pregnant
- Subjects with unstable medical conditions (eg, hypertension)
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: PF-04937319
PF-04937319 Split dose
|
tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
|
Placebo Comparator: Placebo
Placebo split dose
|
tablets, breakfast plus lunch, 7 days
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Aikaikkuna: Baseline up to 14 days after the last dose of study drug (minimum 8 weeks to maximum of 17 weeks)
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.
|
Baseline up to 14 days after the last dose of study drug (minimum 8 weeks to maximum of 17 weeks)
|
Number of Participants With Protocol Defined Hypoglycaemic Adverse Events (HAEs)
Aikaikkuna: Baseline up to 14 days after the last dose of study drug (minimum 8 weeks to maximum of 17 weeks)
|
A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels.
HAE was defined as 1 of the given definitions: 1) Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; 2) Characteristic symptoms of HAE with home glucose monitoring measurement of less than or equal to (=<) 70 milligram per deciliter (mg/dL) using sponsor-provided, plasma-referenced, home glucometers (or central laboratory); 3) any glucose value =<49 mg/dL using sponsor-provided, plasma-referenced, home glucometers (or central laboratory) with or without accompanying symptoms.
|
Baseline up to 14 days after the last dose of study drug (minimum 8 weeks to maximum of 17 weeks)
|
Maximum Observed Plasma Concentration (Cmax) on Day 1 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
|
Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 1 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post-dose on Day 1
|
AUC24 is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose (0 to 24).
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post-dose on Day 1
|
Maximum Observed Plasma Concentration (Cmax) on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
|
Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
AUC24 is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose (0 to 24).
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Pre-dose Plasma Concentration (Ctrough) on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose) on Day 7
|
Ctrough is the concentration prior to study drug administration.
|
0 hour (pre-dose) on Day 7
|
Average Plasma Concentration (Cav) on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Cav is the average plasma concentration during the 0 to 24 hour time period.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Apparent Oral Clearance on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.
It is calculated as the total oral daily dose divided by AUC24, where AUC24 is the area under the plasma concentration-time profile from time 0 to 24 hours.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Terminal Half-Life (t1/2) on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (*) 2/k el, where 'k el' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Only those data points judged to describe the terminal log-linear decline were used in the regression.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
Apparent Volume of Distribution on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose is influenced by the oral bioavailability.
It is calculated as the total oral daily dose divided by AUC24* k el, where AUC24 is the area under the plasma concentration-time profile from time 0 to 24 hours and terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Accumulation Ratio (Rac) on Day 7 for PF-04937319
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Rac is based on AUC24.
It is the ratio of AUC24 of Day 7 and AUC24 of Day 1, where AUC24 is the area under the plasma concentration-time profile from time 0 to 24 hours.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) on Day 1 for PF-06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 for PF-06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 1 for PF--06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
AUC24 is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose (0 to 24).
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
Metabolite to Parent Ratio for AUC24 (MRAUC24) on Day 1
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
MRAUC24 is the ratio of AUC24 of PF-06455349 (metabolite) to AUC24 of PF-04937319 (parent drug) * ratio of molecular weight of PF-04937319 to molecular weight of PF-06455349, where AUC24 is the area under the plasma concentration-time profile from time 0 to 24 hours.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 1
|
Maximum Observed Plasma Concentration (Cmax) on Day 7 for PF--06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 for PF-06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 7 for PF--06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
AUC24 is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose (0 to 24).
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Pre-dose Plasma Concentration (Ctrough) on Day 7 for PF--06455349
Aikaikkuna: 0 hour (pre-dose) on Day 7
|
Ctrough is the concentration prior to study drug administration.
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose) on Day 7
|
Average Plasma Concentration (Cav) on Day 7 for PF--06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Cav is the average plasma concentration during the 0 to 24 hour time period.
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Terminal Half-Life (t1/2) on Day 7 for PF-06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) * 2/k el, where 'k el' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Only those data points judged to describe the terminal log-linear decline were used in the regression.
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24, 36, 48 hours post morning dose on Day 7
|
Accumulation Ratio (Rac) on Day 7 for PF-06455349
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Rac is based on AUC24.
It is the ratio of AUC24 of Day 7 and AUC24 of Day 1, where AUC24 is the area under the plasma concentration-time profile from time 0 to 24 hours.
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Metabolite to Parent Ratio for AUC24 (MRAUC24) on Day 7
Aikaikkuna: 0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
MRAUC24 is the ratio of AUC24 of PF-06455349 (metabolite) to AUC24 of PF-04937319 (parent drug) * ratio of molecular weight of PF-04937319 to molecular weight of PF-06455349, where AUC24 is the area under the plasma concentration-time profile from time 0 to 24 hours.
PF-06455349 is a metabolite of PF-04937319.
|
0 hour (pre-dose), 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 24 hours post morning dose on Day 7
|
Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 7
Aikaikkuna: Pre-morning meal, 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 16 and 20 hours post- morning meal on Day 0; pre-morning dose, 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 16, 20 hours post-morning dose on Day 7
|
WMDG was defined as time-weighted mean daily glucose.
WMDG was calculated by as the time-weighted mean of glucose levels at actual time points for glucose sampling, for Day 0 (Baseline) and Day 7.
|
Pre-morning meal, 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 16 and 20 hours post- morning meal on Day 0; pre-morning dose, 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 16, 20 hours post-morning dose on Day 7
|
Change From Baseline in Fasting Plasma Glucose (FPG) at Last Day of Treatment
Aikaikkuna: Pre-morning meal on Day 0, pre-morning dose on Day 1, pre-morning dose on Day 7, pre-morning meal on Day 8
|
FPG was defined as plasma glucose measurements taken pre-breakfast, in the fasted state, and prior to dosing with study drug.
Baseline was defined as the average of Hour 0 measurements taken on Day 0 and Day 1 in each intervention period.
The measurement on the last day of treatment was defined as the average of Hour 0 measurements taken on Day 7 and Day 8 in each period.
|
Pre-morning meal on Day 0, pre-morning dose on Day 1, pre-morning dose on Day 7, pre-morning meal on Day 8
|
Change From Baseline in Pre-Meal Insulin at Day 7
Aikaikkuna: Pre-morning meal (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) after morning meal on Day 0 (Baseline); pre-morning dose (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) post-morning dose on Day 7
|
Time-matched change from baseline in pre-meal serum insulin on Day 7 of each period was analyzed.
Pre-meal insulin levels therefore, pre-breakfast, pre-lunch, and pre-dinner were analyzed.
|
Pre-morning meal (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) after morning meal on Day 0 (Baseline); pre-morning dose (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) post-morning dose on Day 7
|
Change From Baseline in Pre-Meal C-Peptide at Day 7
Aikaikkuna: Pre-morning meal (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) after morning meal on Day 0 (Baseline); pre-morning dose (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) post-morning dose on Day 7
|
Time-matched change from baseline in pre-meal serum C-peptide on Day 7 of each period was analyzed.
Pre-meal C-peptide levels therefore, pre-breakfast, pre-lunch, and pre-dinner were analyzed.
|
Pre-morning meal (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) after morning meal on Day 0 (Baseline); pre-morning dose (pre-breakfast), 5 hours (pre-lunch), 11 hours (pre-dinner) post-morning dose on Day 7
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Torstai 1. tammikuuta 2015
Ensisijainen valmistuminen (Todellinen)
Sunnuntai 1. maaliskuuta 2015
Opintojen valmistuminen (Todellinen)
Sunnuntai 1. maaliskuuta 2015
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Keskiviikko 12. marraskuuta 2014
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Keskiviikko 12. marraskuuta 2014
Ensimmäinen Lähetetty (Arvio)
Maanantai 17. marraskuuta 2014
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Tiistai 15. maaliskuuta 2016
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 16. helmikuuta 2016
Viimeksi vahvistettu
Maanantai 1. helmikuuta 2016
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- B1621018
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Tyypin 2 diabetes mellitus
-
Griffin HospitalCalifornia Walnut CommissionValmisTYYPIN DIABETES MELLITUS 2Yhdysvallat
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Ei vielä rekrytointiaTyypin 2 diabetes mellitus
-
Endogenex, Inc.Ei vielä rekrytointiaDiabetes mellitus, tyyppi 2 | Diabetes | Tyypin 2 diabetes mellitus | Tyypin 2 diabetes | Tyypin 2 diabetes
-
Nanjing First Hospital, Nanjing Medical UniversityRekrytointiTyypin 2 diabetes mellitusKiina
-
Xiangya Hospital of Central South UniversityRekrytointi
-
University of Alabama at BirminghamValmisTyypin 2 diabetes mellitusYhdysvallat
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...ValmisTyypin 2 diabetes mellitusYhdistynyt kuningaskunta
-
Universiti Sains MalaysiaValmis
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... ja muut yhteistyökumppanitValmisTyypin 2 diabetes mellitus
-
Centre Hospitalier Sud FrancilienValmis
Kliiniset tutkimukset PF-04937319 high dose
-
PfizerValmis
-
PfizerValmis
-
PfizerValmisDiabetes mellitus, tyyppi 2Taiwan, Yhdysvallat, Unkari, Kanada, Slovakia, Intia, Bulgaria
-
University of MinnesotaRekrytointiKiinteiden elinten siirtoYhdysvallat
-
PfizerValmisTyypin 2 diabetes mellitusYhdysvallat, Unkari, Taiwan, Romania, Intia, Etelä-Afrikka, Filippiinit, Slovakia
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Rekrytointi
-
Korean Hemodialysis Study GroupBoryung Pharmaceutical Co., LtdTuntematon
-
Yale UniversityValmisMultippeli myelooma | Influenssa | Waldenströmin makroglobulinemia | MGUS | Plasmasolujen häiriötYhdysvallat
-
Centre Hospitalier Universitaire de NiceRekrytointi
-
Merck Sharp & Dohme LLCValmis